Trial purpose
Cancer treatment
Tumor type
Upper gastrointestinal tract
Age
18+
Clinical summary
Summary
This is a randomised trial with experimental and active comparator arms. Participants in the Experimental arm will receive TAS-120 (Futibatinib) which is an FGFR inhibitor, orally on a 21-day cycle. Participants in the Active Comparator Arm will receive Cisplatin/Gemcitabine whicih is currently 1st line standard of care. Cisplatin 25 mg/m2 in 1000 mL 0.9% saline will be administered intravenously over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline will be administered intravenously over 30 minutes, beginning after completion of the cisplatin and saline infusions.
Conditions
This trial is treating people with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Eligibility
Inclusion
A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- Provide written informed consent.
- Is ≥18 years of age (or meets the country's regulatory definition for legal adult age).
- The patient has histologically confirmed, locally advanced, or metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements based on testing performed by the designated central laboratory.
- Patient has radiographically measurable disease per RECIST 1.1.
- Patients who have received treatment for locally advanced disease (for example, trans-arterial chemoembolization, selective internal radiation therapy, external beam radiation) must have evidence of radiographic progression with measurable disease outside the previously-treated lesions.
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
-
Adequate organ function as defined by the following criteria:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 ×upper limit of normal (ULN); if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN.
- Total bilirubin ≤ 1.5 × ULN, or ≤ 3.0 × ULN for patients with Gilbert's syndrome.
- White Blood Count (WBC) ≥ 2000/mm3 (≥ 2.0 × 109/L)
- Absolute neutrophil count (ANC) ≥ 1000/mm3 (ie, ≥ 1.0 × 109/L by International Units [IU])
- Platelet count ≥ 100,000/mm3 (IU: ≥ 100 × 109/L)
- Hemoglobin ≥ 9.0 g/dL
- Phosphorus ≤ 1.5 × ULN
- Creatinine clearance: ≥ 60 mL/min
- Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to administration of the first dose of futibatinib. Female patients are not considered to be of child bearing potential if they have a history of hysterectomy or are post menopausal defined as no menses for 12 months without an alternative medical cause. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose.
- Willing and able to comply with scheduled visits and study procedures.
Exclusion
A patient will be excluded from this study if any of the following criteria are met:
-
Patient has received previous systemic anticancer therapy.
• Patients receiving adjuvant or neoadjuvant treatment and completed ≥6 months prior to randomization are eligible.
- Patient has mixed hepatocellular carcinoma - iCCA disease.
-
History and/or current evidence of any of the following disorders:
- Non-tumor related alteration of calcium-phosphorus homeostasis that is clinically significant in the opinion of the Investigator.
- Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator.
- Retinal disorder confirmed by retinal examination and considered clinically significant in the opinion of the ophthalmologist.
- History or current evidence of uncontrolled ventricular arrhythmias
- Fridericia's corrected QT interval (QTcF) > 470 ms on electrocardiogram (ECG) conducted during Screening.
-
Treatment with any of the following within the specified time frame prior to the first dose of study therapy, or failure to recover from side effects of these prior therapies:
- Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of study therapy).
- Radiotherapy (any dose) for extended field within 4 weeks or limited field radiotherapy within 2 weeks, and/or has not recovered from acute impact of radiotherapy.
- Patients with locoregional therapy, e.g. transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks.
- Any history of liver transplant.
-
A serious illness or medical condition(s) including, but not limited to, the following:
- Brain metastases that are untreated or clinically or radiologically unstable (that is, have been stable for <1 month).
- Known acute systemic infection.
- Myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure within the previous 6 months.
- Chronic nausea, vomiting, or diarrhea considered to be clinically significant in the opinion of the Investigator.
- Congenital long QT syndrome, or any known history of torsade de pointes, or family history of unexplained sudden death.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- Patients with a history of another primary malignancy that is currently clinically significant, and has potential for metastases or currently requires active intervention.
- Pregnant or breast-feeding female.
- The patient is unable to take oral medication.
Inclusion
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- Your cancer has not spread to other parts of the body (localised).
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Taiho Oncology, Inc
Scientific Title
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information